12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AMR-102: Phase I data

A Phase I trial in 48 healthy volunteers showed that AMR-102 was well tolerated with no serious adverse events reported. Amarin said AMR-102 did not inhibit the bioavailability of either active component of the product compared to...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >